Mid banner advertisement: BDO
Advertisement: Cambridge Network
Advertisement: EBCam mid banner
Advertisement: Mogrify
ARM Innovation Hub
RealVNC mid banner careers
Advertisement: China mid banner
Advertisement EY mid banner
RealVNC mid-banner general
Advertisement: Simpsons Creative
Advertisement: RSM
Barr Ellison Solicitors – commercial property
19 March, 2020 - 11:16 By Kate Sweeney

New CEO steers upward path for NeoPhore

NeoPhore, a small molecule cancer immuno-oncology company anchored in Cambridge, has elevated Dr Matthew Baker to CEO. Dr Baker was previously VP of Immunology and has succeeded Jeff Roix with immediate effect.

Dr Baker has more than 20 years’ experience in the pharmaceutical and biotechnology industries. 

Before joining NeoPhore, he was chief scientific officer of Denceptor Therapeutics Ltd, Abzena plc and CEO and co-founder of Antitope Ltd. Prior to this, he served as VP for Biologics Discovery at Biovation Ltd. 

Dr Baker has a background in B and T cell immunology and completed post-doctoral positions in Cambridge, UK, after obtaining his PhD in cellular immunology at the University of Birmingham.

Robert James, chairman of Neophore, said: “This is an exciting time for NeoPhore as it continues to develop its leading position in DNA mismatch repair (MMR) drug discovery. 

“Matthew’s leadership skills and years of experience as a research expert in cell immunology will prove invaluable as NeoPhore enters the next phase of growth.”

Dr Baker added: “Having been involved in the development of NeoPhore’s drug discovery programmes since June 2019, I am extremely excited by the technology and am delighted to take on the role of CEO. 

“NeoPhore’s highly differentiated approach to targeting MMR has real potential to generate first-in-class next-generation immuno-oncology therapeutics.”

NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. 

Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. 

The company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. 

Using these insights, the company aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. 

NeoPhore was spun-out of PhoreMost Ltd and is backed by Sixth Element Capital LLP, a UK based fund manager established to manage investments for the £70 million CRT Pioneer Fund.

Newsletter Subscription

Stay informed of the latest news and features